Viewing Study NCT02446717



Ignite Creation Date: 2024-05-06 @ 4:03 AM
Last Modification Date: 2024-10-26 @ 11:43 AM
Study NCT ID: NCT02446717
Status: COMPLETED
Last Update Posted: 2017-09-15
First Post: 2015-05-14

Brief Title: A Study to Evaluate the Efficacy Safety and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy
Sponsor: AbbVie
Organization: AbbVie

Study Overview

Official Title: A Randomized Open-Label Multicenter Study to Evaluate the Efficacy Safety and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 or ABT-493ABT-530 With and Without Ribavirin in Adults With Chronic Hepatitis C Virus HCV Infection Who Failed a Prior Direct-Acting Antiviral Agent DAA-Containing Therapy
Status: COMPLETED
Status Verified Date: 2017-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to assess the efficacy and safety of ABT-493 and ABT-530 with or without ribavirin RBV in participants with chronic hepatitis C virus HCV-infection who previously failed treatment with a direct acting antiviral DAA-containing regimen
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2015-002350-13 EUDRACT_NUMBER None None